Experienced Doctors

Premranjan Singh, MD, MD

Interventional Cardiologist

Dr. Premranjan Singh works in Ocala, FL and specializes in Cardiovascular Disease. Dr. Singh is affiliated with Munroe HMA Hospital LLC, O'Callaghan Regional Medical Center and West Marion Community Hospital.

Request Opinion Schedule in-person visit

Dr. Premranjan Singh specializes in Cardiovascular disease and practices Ocala, FL and 1 more location. Dr. Singh is affiliated with Munroe HMA Hospital LLC, Ocallaghan Regional Medical Center and West Marion Community Hospital. He has won a number of awards to his credit and has published more than 20 articles in this field. 

  • Interventional Cardiology Fellowship Lahey Clinic, Burlington, MA
  • Cardiovascular Disease Fellowship, Lahey Clinic, Burlington, MA
  • Research Fellowship, Department of Cardiology, Lahey Clinic, MA
  • Residency Internal Medicine, University of Illinois College of Medicine, IL
  • Staff Physician, Cardiology, Interventional Cardiology, Vascular medicine and Internal Medicine at Monroe Regional Medical Center, Ocala Régional Medical Center  and West Marion Cumunity Hospital. Ocala, FL
  • CVI (Private Practice) Interventional cardiology/Vascular Medicine / Cardiology / Internal Medicine,  Ocala, FL
  • Urban Cardiology (Privat practice) Interventional cardiology/Vascular Medicine / Cardiology / Internal Medicine,  Ocala, FL
  • Marion Heart Associate  (Private Practice) Interventional Cardiology/Vascular Medicine / Cardiology/ Internal Medicine, Ocala, FL
  • Interventional Cardiology Board Certification (ABIM)
  • Cardiology Board Certification (ABIM)
  • Certification Board of Echocardiography (ASE)
  • Certification American Board of Vascular Medicine (ABVM)
  • Certification American Board of Vascular Medicine (Endovascular)
  • Florida Medical License
  • Certification Board of Nuclear Cardiology (CBNC)
  • American Board of Internal Medicine (ABIM) Certification
  • ECFMG Certification
  • Chair, Peripheral Arterial Disease (PAD) writing group, Bypass Angioplasty Revascularization Investigation in type 2 Diabetes (BARI 2D)
  • Member, Symptom Writing group, Bypass Angioplasty Revascularization Investigation in type 2 Diabetes (BARI 2D) 
  • Society for Cardiac Angiography and Interventions (SCAI)
  • Member, American College of Cardiology (ACC)
  • Member, American Heart Association
  • Member, American College of Physicians
  • Member, American Medical Association
  • Member, Red Cross Society 1999 - MD with HONORS, P.M.C.H.
  • Dean List, Medical College.
  • Abbott JD, Lombardero MS, Barsness GW, Singh PP, Woodhead G, Kelsey SF. Ankle-brachial index and cardiovascular outcomes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial. Am Heart J. 2012 Oct;164(4):585-590.e4. doi: 10.1016/j.ahj.2012.06.017. PMID: 23067918  
  • Singh PP, Abbott JD, Lombardero MS, Piemonte TC, Lago RM, Rutter MK, Nesto RW; Bypass Angioplasty Revascularization Investigation 2 Diabetes Study Group. The prevalence and predictors of an abnormal ankle-brachial index in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Diabetes Care. 2011 Feb;34(2):464-7  
  • BARI 2D Study Group, Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, Sobel BE. A randomized trial of therapies for type 2 diabetes and coronary artery disease N Engl J Med. 2009 Jun 11;360(24):2503-15. Epub 2009 Jun 7. PMID: 19502645 [PubMed - indexed for MEDLINE]  
  • Pop-Busui R, Lu J, Lopes N, Jones TL; BARI 2D Investigators. Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohort.,J Peripher Nerv Syst. 2009 Mar;14(1):1-13. PMID: 19335534  
  • Bypass Angioplasty Revascularization Investigation 2 Diabetes Study Group. Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.Am Heart J. 2008 Sep;156(3):528-536, 536.e1-5. Epub 2008 Jul 31.PMID: 18760137  
  • Vidi V, Rajesh V, Singh PP, Mukherjee JT, Lago RM, Waxman S, Nesto RW: Clinical characteristics of tako-tsubo cardiomyopathy Am J Cardiol. 2009 Aug 15; 104(4):578-82. Epub 2009 Jun 18    
  • Vidi V, Singh PP, Alhumaid AC, Lee RS, Kinnunen PM: Hydropneumopericardium presenting as an acute coronary syndrome: a rare complication of paraesophageal hernia, Tex Heart Inst J. 2009;36(3):255-8.  
  • Singh PP, Lago RM, Nesto RW: Myocardial Glucose Transport and Utilization: A Target for Therapeutic Intervention Rev Cardiovasc Med. 2008; 9(2)
  • Lago RM, Singh PP, Nesto RW:  Obesity, Type 2 Diabetes, and Cardiovascular Disease:  CME, Baylor college of Medicine Reports on Cardiometabolic Disorders, Vol 2, Number1, www.lipidsonline.org  
  • Vidi V, Singh PP, Nesto PP: Tako-tsubo syndrome following a difficult urinary catheterization, Int J Cardiol. 2008 Jun 3.  
  • Ishibashi F, Mizuno K, Singh PP, Nesto PP, Waxman S: High Yellow Color Intensity by Angioscopy With Quantitative Colorimetry to Identify High-Risk Features in Culprit Lesions of Patients With Acute Coronary Syndromes ? ?American Journal of Cardiology ?15 October 2007 Vol. 100, Issue 8, Pages 1207-1211.  
  • Lago RM, Singh PP, Nesto RW: Diabetes and hypertension.: Nat Clin Pract Endocrinol Metab. 2007 Oct ;3 (10):667   
  • Lago RM, Singh PP, Nesto RW: Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomized clinical trials. Lancet. 2007 Sep 29;370 (9593):1129-36    
  • Singh PP, Lago RM, Nesto RW: Do nondiabetic patients with acute coronary syndromes and hyperglycemia benefit from insulin therapy? Nat Clin Pract Cardiovasc Med. 2008 Mar 18;  18349825
  • Nesto RW, Singh PP: Diabetes and residual risk of coronary heart disease. Nature Clin Pract Endocrinol Metab. 2007 Feb;3(2):71. 
  • Singh PP, Nesto RW, Faxon DP, Lepor NE, Watson KE, Jacobs AK, McCullough PA. Best of the AHA Scientific Sessions 2006.Rev Cardiovasc Med. 2007 Winter;8(1): 25-35
  • Singh PP, Nesto RW, Myocardial Glucose transport and utilization: A Target For Therapeutic Intervention. Rev Cardiovasc Med. 2007 (In Press)  
  • Singh PP, Rutter MK, Lombardero MS, Piemonte TC, Nesto RW: Prevalence and Clinical Predictors of High Ankle Brachial Index in Patients with Type 2 Diabetes and CHD in the BARI-2D Trial. Abstract/Poster presentation ADA Chicago 2007.  
  • Woodhead GA, Massaro EM, Lombardero M, Singh PP: Significance of Measuring Ankle-Brachial Index in the Type 2 Diabetic Patients with Coronary Artery Disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes Trial. [BARI 2D] abstract Vascular Nursing Meeting  Maryland 2007.
  • Singh PP, Abbott DJ, Lombardero MS, Piemonte TC, Nesto RW: Prevalence and Clinical Characteristics of Peripheral Artery Disease in Patients with Type 2 Diabetes and CAD Enrolled in The BARI 2D Trial. Abstract/Poster presentation AHA Chicago 2006
  • Ishibashi F, Mizuno K, Kawamura A, Singh PP, Waxman S.: Frequency of non-culprit thin –cap lipid cores in myocardial infarction and stable angina. Abstract SCAI 2006
  • Singh PP, Kocheril A; Use of IV Nesiritide in End Stage Renal Disease and Heart Failure. A Poster Presentation to ACP Illinois chapter 2003.